SCHEMBL6586180

SCHEMBL6586180

Cn1cc(C2=C(c3cccc(N4CCOCC4)c3)C(=O)NC2=O)c2ccccc21

nearest known ligand 0.69

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 8/20 0.69
PRKCA P17252 5/20 0.67
CCNE2 O96020 1/20 0.59
CDK4 P11802 1/20 0.59
CCND1 P24385 1/20 0.59
CCNE1 P24864 1/20 0.59
CDK2 P24941 1/20 0.59
PRKCB P05771 2/20 0.56
PRKCE Q02156 2/20 0.56
PRKCG P05129 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6582692 0.99 GSK3B (0.67) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL7530443 0.89 GSK3B (0.72) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL7079465 0.86 GSK3B (0.64) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL7990993 0.83 CDK2 (0.67) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL29359337 0.80 GSK3B (1.00) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL4427029 0.80 GSK3B (1.00) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL29396453 0.80 GSK3B (1.00) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL6584593 0.80 GSK3B (0.72) GSK3BPRKCAPRKCBPRKCG
SCHEMBL8154180 0.79 GSK3B (0.76) GSK3BPRKCACCNE2CDK4CCND1
SCHEMBL7986966 0.79 PRKACA (0.66) GSK3BPRKCACCNE2CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156582-A1 Pyrazole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156582-A1 Pyrazole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
EP-1307447-B1 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA HOFFMANN LA ROCHE (CH) 2004-12-15 EP disclosed
EP-1307447-A2 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA F. HOFFMANN-LA ROCHE AG (CH) 2003-05-07 EP disclosed
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GONG LEYI (US) 2002-12-12 US disclosed
US-6479490-B2 TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. SYNTEX (U.S.A.) LLC 2002-11-12 US disclosed
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta SYNTEX (U.S.A.) LLC 2002-05-02 US disclosed
WO-2002010158-A2 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA F. HOFFMANN-LA ROCHE AG (CH) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052397-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL GSK3B 1/4885PRKCA 61/4885CCNE2 1424/4885
US-20020188018-A1 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta GSK3B, GSK3A, PYGL GSK3B 1/4885PRKCA 62/4885CCNE2 2037/4885
US-20090156582-A1 Pyrazole Compound GSK3B, GSK3A, GSKIP GSK3B 1/4885PRKCA 414/4885CCNE2 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.